Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.6%. By the end of trading, Bristol-Myers Squibb Company fell $0.58 (-1.3%) to $44.61 on light volume. Throughout the day, 4,931,582 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10,686,300 shares. The stock ranged in price between $44.51-$45.39 after having opened the day at $45.21 as compared to the previous trading day's close of $45.19. Other companies within the Drugs industry that declined today were:
), down 35.9%,
), down 18.9%,
), down 15.6% and
), down 12.2%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $73.9 billion and is part of the health care sector. Shares are up 38.1% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.
TheStreet Ratings rates
Bristol-Myers Squibb Company
. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Bristol-Myers Squibb Company Ratings Report.
On the positive front,
), up 14.5%,
), up 13.0%,
), up 11.8% and
), up 10.6% , were all gainers within the drugs industry with
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.